Advancements in Surgical Interventions in nAMD and DME

Advancements in Surgical Interventions in nAMD and DME is organized by Healio, Vindico Medical Education.

This enduring material is approved for 1 year from the date of original release, June 30, 2022, to June 29, 2023.

Activity Description:
Although greatly improved by anti-VEGF therapy, the treatment of patients with retinal vascular diseases is still less than ideal. Suboptimal injection frequency often occurs as a result of the high treatment burden, and a substantial number of patients do not respond well to current anti-VEGF agents. To address these problems, new delivery methods are under investigation to provide continuous dosing over a longer period of time. The recent approval of the port delivery system for anti-VEGF therapy has not only revolutionized the treatment of patients with into the current treatment algorithm for neovascular age-related macular degeneration (nAMD) but also necessitates timely education for retina specialists regarding best practices for the use of this device and expert recommendations for the prevention and management of complications. Moreover, since other delivery methods such as subretinal and suprachoroidal delivery of investigational gene therapies are in late-stage development, clinicians also need to know not only the available clinical data of these agents but also the practical information regarding how these therapies are administered. In this educational activity, experts in the field of retinal vascular diseases review the clinical data supporting the use of novel drug delivery systems for nAMD and provide practical guidance for the use of these agents.

Learning Objectives:
Upon successful completion of this activity, participants should be better able to:
• Incorporate novel surgical advances that can enhance outcomes in patients with retinal vascular diseases, by reducing treatment burden.
• Detail procedural steps and surgical techniques that are necessary when using the Port Delivery System (PDS) with ranibizumab, as well as with gene therapy in patients with retinal vascular diseases.
• Utilize techniques that improve the refilling and exchange of the PDS with ranibizumab in patients with retinal vascular disease.
• Recognize processes and procedures that can reduce complications from surgeries that involve the use of the PDS with ranibizumab, as well as with gene therapy for retinal vascular diseases.